Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 4.8779
Recommendation BUY
P/E 38.33
ROE 29.98 %
Capitalization 70,789,686,000 $
Dividend Yield 0.00 %
P/S 4.63
AII Position 142
P/E Position 512
ROE Position 98
Capitalization Position 132
Dividend Yield Position 594
Sales 15,281,000,000 $
10-Year Average Earnings 1,846,838,900 $
Shares Outstanding 733,800,000
Equity 6,161,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2018 12 15,281,000,000.00 $
2017 12 13,003,000,000.00 $
2016 12 11,229,000,000.00 $
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 4,046,000,000.00 $
2017 12 2,940,000,000.00 $
2016 12 1,999,000,000.00 $
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 6,161,000,000.00 $
2017 12 6,921,000,000.00 $
2016 12 6,600,000,000.00 $
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 733,800,000
2017 12 808,700,000
2016 12 803,300,000
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:



Google News for CELGENE:

Yahoo Finance - 1 day ago
Why Is Celgene (CELG) Up 1.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Celgene (CELG). Shares have added about 1.4% in that time frame, outperforming the ...
The EN Herald
My Top Merger-Arb Pick: Celgene
One name to consider is Celgene (CELG). Bristol-Myers Squibb (BMY) is buying Celgene in a cash and stock deal. The merger already has ...
CryptoCoinsTribune
Valuing Celgene's Contingent Value Rights
Celgene (CELG) has seen its stock price improve dramatically since it was announced it would be acquired by Bristol-Myers Squibb (BMY).
The NBO News
Is Celgene (CELG) Outperforming Other Medical Stocks This Year?
Celgene (CELG) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a ...
Seeking Alpha - 3 days ago
Celgene (CELG) Shareholder Wedbush Securities Has Cut Stake ...
Wedbush Securities Inc decreased its stake in Celgene Corp (CELG) by 18.76% based on its latest 2018Q4 regulatory filing with the SEC.
Seeking Alpha - 16 May 2019
All You Need to Know About Celgene (CELG) Rating Upgrade to Buy
Investors might want to bet on Celgene (CELG), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an ...
Yahoo Finance - 1 May 2019
Spears Abacus Advisors Has Lowered Celgene (CELG) Stake by ...
Spears Abacus Advisors Llc decreased its stake in Celgene Corp (CELG) by 8.93% based on its latest 2018Q4 regulatory filing with the SEC.
The EN Herald - 11 hours ago
Celgene (CELG) Holder Affinity Investment Advisors Has Cut ...
Affinity Investment Advisors Llc decreased its stake in Celgene Corp (CELG) by 9.92% based on its latest 2018Q4 regulatory filing with the SEC ...
Yahoo Finance - 1 May 2019
Bristol-Myers Stock Is Falling Because the Celgene Merger May Not ...
Pharmaceutical behemoth Bristol-Myers Squibb (ticker: BMY) is preparing for the purchase of Celgene (CELG), a major biotech company, for a ...
The EN Herald - 17 hours ago
Garrison Bradford & Associates Decreased Its Celgene (CELG ...
Garrison Bradford & Associates Inc decreased its stake in Celgene Corp (CELG) by 7.37% based on its latest 2018Q4 regulatory filing with the ...


Back